as 07-26-2024 4:00pm EST
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Founded: | 1994 | Country: | United States |
Employees: | N/A | City: | ALAMEDA |
Market Cap: | 6.6B | IPO Year: | 2000 |
Target Price: | $26.64 | AVG Volume (30 days): | 1.3M |
Analyst Decision: | Buy | Number of Analysts: | 14 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.64 | EPS Growth: | 33.33 |
52 Week Low/High: | $18.64 - $24.34 | Next Earning Date: | 08-06-2024 |
Revenue: | $1,846,646,000 | Revenue Growth: | 10.98% |
Revenue Growth (this year): | 4.58% | Revenue Growth (next year): | 9.87% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
WYSZOMIERSKI JACK L | EXEL | Director | Jun 4 '24 | Sell | $22.00 | 8,287 | $182,314.00 | 349,499 | SEC Form 4 |
JOHNSON DAVID EDWARD | EXEL | Director | May 28 '24 | Buy | $20.76 | 225,000 | $4,670,055.00 | 1,525,730 | SEC Form 4 |
JOHNSON DAVID EDWARD | EXEL | Director | May 28 '24 | Buy | $20.32 | 200,000 | $4,063,900.00 | 1,300,730 | SEC Form 4 |
POSTE GEORGE | EXEL | Director | May 21 '24 | Sell | $20.96 | 11,686 | $244,938.56 | 213,907 | SEC Form 4 |
Smith Julie | EXEL | Director | May 21 '24 | Sell | $21.12 | 27,280 | $576,153.60 | 5,445 | SEC Form 4 |
PAPADOPOULOS STELIOS | EXEL | Director | May 20 '24 | Sell | $21.00 | 11,437 | $240,177.00 | 1,260,578 | SEC Form 4 |
WYSZOMIERSKI JACK L | EXEL | Director | May 13 '24 | Sell | $21.37 | 10,923 | $233,424.51 | 338,948 | SEC Form 4 |
Garber Alan M | EXEL | Director | Mar 21 '24 | Sell | $24.01 | 19,205 | $461,112.05 | 35,703 | SEC Form 4 |
Haley Patrick J. | EXEL | EVP, Commercial | Feb 23 '24 | Sell | $21.45 | 47,020 | $1,008,579.00 | 384,866 | SEC Form 4 |
JOHNSON DAVID EDWARD | EXEL | Director | Feb 21 '24 | Buy | $20.70 | 190,000 | $3,932,734.00 | 1,100,730 | SEC Form 4 |
Hessekiel Jeffrey | EXEL | EVP, General Counsel & Sec | Dec 13 '23 | Sell | $23.01 | 25,000 | $575,250.00 | 533,345 | SEC Form 4 |
Haley Patrick J. | EXEL | EVP, Commercial | Dec 12 '23 | Sell | $22.50 | 14,149 | $318,352.50 | 307,687 | SEC Form 4 |
Haley Patrick J. | EXEL | EVP, Commercial | Dec 12 '23 | Sell | $23.35 | 50,000 | $1,167,500.00 | 307,687 | SEC Form 4 |
Hessekiel Jeffrey | EXEL | EVP, General Counsel & Sec | Nov 30 '23 | Sell | $22.01 | 25,000 | $550,250.00 | 583,345 | SEC Form 4 |
Hessekiel Jeffrey | EXEL | EVP, General Counsel & Sec | Nov 30 '23 | Sell | $22.06 | 25,000 | $551,500.00 | 558,345 | SEC Form 4 |
JOHNSON DAVID EDWARD | EXEL | Director | Nov 27 '23 | Sell | $21.61 | 120,409 | $2,602,038.49 | 790,321 | SEC Form 4 |
JOHNSON DAVID EDWARD | EXEL | Director | Nov 27 '23 | Buy | $21.61 | 120,409 | $2,602,038.49 | 910,730 | SEC Form 4 |
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
Business Wire
3 days ago
Argus Research
10 days ago
Argus Research
17 days ago
Simply Wall St.
a month ago
Morningstar Research
a month ago
ACCESSWIRE
2 months ago
Business Insider
2 months ago
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.